Aurobindo Pharma Limited (AUROPHARMA) Net Income 2023–2026

Name: Aurobindo Pharma Limited (AUROPHARMA) net income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Aurobindo Pharma Limited annual net income for fiscal 2026 was ₹35.0 billion, an increase of 0.5% from ₹34.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

AUROPHARMA Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	₹35.0B	₹34.9B	₹31.7B	₹19.3B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUROPHARMA Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Net Income	₹10.3B	₹9.2B	₹9.1B	₹8.2B	₹9.0B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4151 Net Income — Kyowa Kirin Co., Ltd.
ZYDUSLIFE Net Income — Zydus Lifesciences Limited
CIPLA Net Income — Cipla Limited
LAURUSLABS Net Income — Laurus Labs Limited
DRREDDY Net Income — Dr. Reddy's Laboratories Limited
LUPIN Net Income — Lupin Limited

More AUROPHARMA metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All AUROPHARMA financial statements → Interactive AUROPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.